Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Phase 1, Open-label, Multicenter, Safety and Pharmacokinetic Study of EDI200

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Edimer Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01564225
First received: March 23, 2012
Last updated: November 25, 2013
Last verified: November 2013

March 23, 2012
November 25, 2013
May 2012
April 2013   (final data collection date for primary outcome measure)
Number of participants with adverse events [ Time Frame: Up to 42 days ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01564225 on ClinicalTrials.gov Archive Site
Exploratory endpoint: change from baseline in biological activity [ Time Frame: Baseline and 42 days ] [ Designated as safety issue: No ]
  • Hair number and growth properties
  • Pulmonary function and eNO levels
  • Sweat duct density
  • Sweat rate
  • Saliva quantitation
  • Tearing and dry eye evaluation
  • Skin biopsy for expression profile
Same as current
Not Provided
Not Provided
 
A Phase 1, Open-label, Multicenter, Safety and Pharmacokinetic Study of EDI200
A Phase 1, Open-label, Multicenter, Safety and Pharmacokinetic Study of EDI200, an Ectodysplasin-A1 Replacement Molecule, in X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) Adults

Following discussions with the FDA, a Phase 1 safety study is being initiated in X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)-affected adults to develop safety and exposure data for EDI200 in anticipation of dosing XLHED-affected neonates. Selecting XLHED-affected adults for this study provides a genetic match and biologic relevance to XLHED-affected neonates. Both males and females will be enrolled, providing safety experience with EDI200 that will inform the planned neonate study as well as supportive data for potential future trials of antenatal EDI200 administration.

The Phase 1 study will enroll two cohorts of 3 XLHED-affected adults each, for a total of 6 subjects. The size and scope of the study design are consistent with a drug development program in an ultra-rare disease and supported by the absence of safety concerns in a GLP non-human primate toxicology study. All subjects must meet entry criteria including documentation of an EDA mutation. Mirroring the conditions of use anticipated for the XLHED-affected newborn study, the adult cohort study incorporates a multiple-dose regimen associated with maximal efficacy in the newborn canine model. Primary outcome measures will be safety, tolerability, immunogenicity and pharmacokinetics (PK). While current data does not support a likelihood of clinical benefit for the XLHED-affected adult subjects, assays of pharmacodynamic/biologic activity are incorporated into the study design as exploratory objectives.

Interventional
Phase 1
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
X-linked Hypohidrotic Ectodermal Dysplasia
Drug: EDI200
Cohort 1 will be dosed at 3 mg/kg/dose. Cohort 2 will be dosed at 10 mg/kg/dose. Both cohorts will receive 2 doses/week for a total of 5 doses.
Experimental: EDI200
Intervention: Drug: EDI200
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
6
April 2013
April 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Males and females of child-bearing age, age 18-40 years
  2. Weight between 45 and 90 kg and a body mass index (BMI) from 18 to 29 kg/m2 (calculated using the following formula: weight in kilograms/(height in meters)2)
  3. Both males and females must be documented (via genetic testing) to carry an EDA mutation associated with XLHED; or have the clinical signs and symptoms associated with HED and/or a family history of HED and provide a blood sample to be sent for genetic testing that confirms an EDA mutation associated with XLHED
  4. No major medical issues that the investigator considers to be a contraindication of participation
  5. No scalp shaving in the month prior to first dose (males only)
  6. Women must use a "highly effective" method of contraception throughout the trial. Highly effective methods of birth control are defined as those, alone or in combination, which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly. These methods include implants, injectables, oral contraceptives, some intrauterine contraceptive devices, sexual abstinence, tubal ligation or a vasectomized partner.
  7. No treatment with an investigational drug within the last three months
  8. Signed written informed consent

Exclusion Criteria:

  1. Women who are pregnant (confirmed via urine pregnancy test) or breastfeeding at screening or planning to become pregnant at any time during the study period
  2. Known history of hepatitis B surface antigen (HBsAg) or hepatitis C (HCV) antibody
  3. Known history of HIV infection
  4. Known hypersensitivity to pilocarpine or pilocarpine-like muscarinic agonists
  5. Known hypersensitivity to lidocaine or lidocaine-like agents
  6. Presence of pacemakers
  7. Subjects who are not able or are not willing to comply with the procedures of this protocol
  8. Subject has a condition which in the opinion of the investigator would not allow for safe conduct of the study
Both
18 Years to 40 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01564225
ECP-004
Yes
Edimer Pharmaceuticals
Edimer Pharmaceuticals
Not Provided
Principal Investigator: Ophir Klein, MD, PhD University of California, San Francisco
Principal Investigator: James Maynard, MD Community Research
Edimer Pharmaceuticals
November 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP